2021.11.09 I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC
2021.11.08 I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab’s Innovative Pipeline at the 4th CIIE
2021.11.04 I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins’s Lymphoma at ASH 2021
2021.11.01 I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments
2021.10.26 I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China
2021.10.18 I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
2021.10.13 I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China